Talus Bio’s first programs focus on oncology. Transcription factor dysfunction is also pervasive across inflammatory, fibrotic, neurological, and cardiometabolic disorders, providing a rich landscape for future drug development.
TBXT Chordoma Program
Chordoma is a spinal cord cancer that is resistant to chemotherapy. Chordoma growth is driven by the transcription factor TBXT. Our compound is the first inhibitor of TBXT, selectively killing chordoma cancer cells.